Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Long-Term Investments: 2019-2025

Historic Long-Term Investments for Intellia Therapeutics (NTLA) over the last 6 years, with Sep 2025 value amounting to $158.8 million.

  • Intellia Therapeutics' Long-Term Investments fell 44.58% to $158.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.8 million, marking a year-over-year decrease of 44.58%. This contributed to the annual value of $260.2 million for FY2024, which is 160.57% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Long-Term Investments of $158.8 million as of Q3 2025, which was down 7.05% from $170.9 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Long-Term Investments high stood at $350.5 million for Q3 2021, and its period low was $16.7 million during Q1 2021.
  • In the last 3 years, Intellia Therapeutics' Long-Term Investments had a median value of $170.9 million in 2025 and averaged $192.5 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first surged by 7,005.33% in 2021, then crashed by 88.56% in 2022.
  • Over the past 5 years, Intellia Therapeutics' Long-Term Investments (Quarterly) stood at $337.4 million in 2021, then plummeted by 79.45% to $69.3 million in 2022, then skyrocketed by 44.02% to $99.9 million in 2023, then soared by 160.57% to $260.2 million in 2024, then plummeted by 44.58% to $158.8 million in 2025.
  • Its last three reported values are $158.8 million in Q3 2025, $170.9 million for Q2 2025, and $203.4 million during Q1 2025.